Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

Trastuzumab is a successful rationally designed ERBB2-targeted therapy. However, about half of individuals with ERBB2-overexpressing breast cancer do not respond to trastuzumab-based therapies, owing to various resistance mechanisms. Clinically applicable regimens for overcoming trastuzumab resistance of different mechanisms are not yet available. We show that the nonreceptor tyrosine kinase c-SRC (SRC) is a key modulator of trastuzumab response and a common node downstream of multiple trastuzumab resistance pathways. We find that SRC is activated in both acquired and de novo trastuzumab-resistant cells and uncover a novel mechanism of SRC regulation involving dephosphorylation by PTEN. Increased SRC activation conferred considerable trastuzumab resistance in breast cancer cells and correlated with trastuzumab resistance in patients. Targeting SRC in combination with trastuzumab sensitized multiple lines of trastuzumab-resistant cells to trastuzumab and eliminated trastuzumab-resistant tumors in vivo, suggesting the potential clinical application of this strategy to overcome trastuzumab resistance.     

Cloning and characterization of two new thermostable and alkalitolerant α-amylases from the <Emphasis Type="Italic">Anoxybacillus</Emphasis> species that produce high levels of maltose

Two genes that encode α-amylases from two Anoxybacillus species were cloned and expressed in Escherichia coli. The genes are 1,518 bp long and encode 506 amino acids. Both sequences are 98% similar but are distinct from other well-known α-amylases. Both of the recombinant enzymes, ASKA and ADTA, were purified using an α-CD–Sepharose column. They exhibited an optimum activity at 60°C and pH 8. Both amylases were stable at pH 6–10. At 60°C in the absence of Ca²⁺, negligible reduction in activity for up to 48 h was observed. The activity half-life at 65°C was 48 and 3 h for ASKA and ADTA, respectively. In the presence of Ca²⁺ ions, both amylases were highly stable for at least 48 h and had less than a 10% decrease in activity at 70°C. Both enzymes exhibited similar end-product profiles, and the predominant yield was maltose (69%) from starch hydrolysis. To the best of our knowledge, most α-amylases that produce high levels of maltose are active at an acidic to neutral pH. This is the first report of two thermostable, alkalitolerant recombinant α-amylases from Anoxybacillus that produce high levels of maltose and have an atypical protein sequence compared with known α-amylases.     

Effective Equine Immunization Protocol for Production of Potent Poly-specific Antisera against Calloselasma rhodostoma,Cryptelytrops albolabris and Daboia siamensis

Snake envenomation has been estimated to affect 1.8 million people annually with about 94,000 deaths mostly in poor tropical countries. Specific antivenoms are the only rational and effective therapy for these cases. Efforts are being made to produce effective, affordable and sufficient antivenoms for these victims. The immunization process, which has rarely been described in detail, is one step that needs to be rigorously studied and improved especially with regard to the production of polyspecific antisera. The polyspecific nature of therapeutic antivenom could obviate the need to identify the culprit snake species. The aim of this study was to produce potent polyspecific antisera against 3 medically important vipers of Thailand and its neighboring countries, namely Cryptelytrops albolabris "White lipped pit viper" (CA), Calleoselasma rhodostoma “Malayan pit viper” (CR), and Daboia siamensis “Russell’s viper” (DS). Four horses were immunized with a mixture of the 3 viper venoms using the ‘low dose, low volume multi-site’ immunization protocol. The antisera showed rapid rise in ELISA titers against the 3 venoms and reached plateau at about the 8th week post-immunization. The in vivo neutralization potency (P) of the antisera against CA, CR and DS venoms was 10.40, 2.42 and 0.76 mg/ml, respectively and was much higher than the minimal potency limits set by Queen Soavabha Memorial Institute (QSMI). The corresponding potency values for the QSMI monospecific antisera against CA, CR and DS venoms were 7.28, 3.12 and 1.50 mg/ml, respectively. The polyspecific antisera also effectively neutralized the procoagulant, hemorrhagic, necrotic and nephrotoxic activities of the viper venoms. This effective immunization protocol should be useful in the production of potent polyspecific antisera against snake venoms, and equine antisera against tetanus, diphtheria or rabies.     

Molecular analysis of a novel FMRFamide-related peptide gene (SOFaRP(2)) and its expression pattern in the brain of the European cuttlefish Sepia officinalis

FMRFamide-related peptides (FaRPs) are among several neurotransmitters known to regulate the chromatophore function in the European cuttlefish Sepia officinalis. Here we report the cloning and sequencing of a novel S. officinalis FaRP gene (SOFaRP(2)). The complete 835-base pair cDNA sequence of the SOFaRP(2) gene contains an open reading frame of 567 base pairs encoding 188 amino acids and four putative FaRPs, NSLFRFamide, GNLFRFamide, TIFRFamide and PHTPFRFamide. All except TIFRFamide cause chromatophore expansion when assayed in an in vitro chromatophore bioassay. To investigate the expression pattern of SOFaRP(2) gene in the cuttlefish brain, in situ hybridization was performed using a full length RNA probe. The SOFaRP(2) gene was expressed primarily in the posterior chromatophore, anterior chromatophore, lateral basal and optic lobes among other brain locations. The SOFaRP(2) gene appears to be expressed in all brain regions involved in chromatophore regulation. These data suggests that some or all of the four FaRPs encoded by SOFaRP(2) might be involved in controlling chromatophore activity in cuttlefish.     

Setting sail for glucose homeostasis with the AKAP150‐PP2B‐anchor

EMBO J (2012) 31 20, 3991–4004 doi:10.1038/emboj.2012.244; published online August312012Glucose-stimulated insulin secretion, controlled by multiple protein phosphorylation events, is critical for the regulation of glucose homeostasis. Protein kinase A (PKA) is known to play a role in β cell physiology, but the role of its anchoring protein is not fully understood. Hinke et al (2012) illustrate the significance of A-kinase anchoring protein 150 in tethering protein phosphatase 2B to mediate nutrient-stimulated insulin secretion and thus modulate glucose homeostasis.Insulin secretion is a key component in the regulation of glucose homeostasis. The initiation of glucose-stimulated insulin secretion (GSIS) is coordinated by numerous protein phosphorylation and dephosphorylation events in the β cell (Jones and Persaud, 1998). PKA and protein phosphatase 2B (PP2B or calcineurin—a Ca²⁺/calmodulin-dependent enzyme) are examples of enzymes that can influence the release of insulin. The combined effects of these enzymes propagate GSIS, which is mediated intracellularly via an increase in ATP concentration, Ca²⁺ influx via the voltage-dependent Ca²⁺ channel (VDCC) and cyclic AMP (cAMP) signalling. At the same time, these enzymes can also regulate glucose usage (e.g., via glycogen synthase) in insulin-sensitive tissues such as the skeletal muscle.cAMP signalling serves to potentiate GSIS via either (1) PKA-dependent or (2) PKA-independent mechanisms (involving cAMP-binding protein Epac2A (exchange protein directly activated by cAMP 2)). A-kinase anchoring protein (AKAP) belongs to a group of regulatory proteins that interacts with cAMP-dependent PKA (Pidoux and Tasken, 2010; Welch et al, 2010). It can regulate the differential usage of kinase versus phosphatase, thereby controlling metabolic outcomes in specific tissues. Although it is known that PKA phosphorylation regulates β cell physiology, the role of such anchoring proteins is less clear (Faruque et al, 2009; Lester et al, 2001). For example, while disruption of the AKAP–PKA interaction has been reported to decrease insulin secretion (Lester et al, 1997), the specific regulatory protein that anchors PKA has yet to be identified.In this study, Hinke et al (2012) sought to identify the specific anchoring protein that tethers PKA, and to elucidate its function. Two AKAP proteins, namely, AKAP150 and AKAP220 were first shortlisted from an overlay assay used to detect RII (regulatory subunit of PKA) binding proteins. Subsequently, only AKAP150 was found to be important for nutrient-stimulated insulin secretion. Mice with a global knockout of AKAP150 (AKAP150KO) exhibited insulin secretory defects. AKAP150 binds to and regulates the phosphorylation-dependent VDCC. Thus, these AKAP150KO mice exhibited decreased basal Ca²⁺ current and glucose-stimulated Ca²⁺ influx in isolated β cells. One reason for the decrease in Ca²⁺ current could be attributed to a mislocation of its binding partner PP2B (discussed below). Glucose-stimulated cAMP fluctuation which is necessary for insulin secretion (Dyachok et al, 2008) was also abolished in AKAP150KO mice. Therefore, AKAP150KO mice exhibit an insulin secretory defect due to multiple impairments including (1) decreased Ca²⁺ influx and (2) defective cAMP production.Surprisingly, while the authors report that global AKAP150KO mice secrete less insulin, the skeletal muscle, an insulin-sensitive peripheral tissue, exhibited improved blood glucose clearance likely due to increased phosphorylation of IRS-1 and Akt/PKB, and activation of AMPK that resulted in improved insulin sensitivity. On the other hand, β cell-specific AKAP150KO mice secrete less insulin upon glucose stimulation despite increased insulin content in the β cell that occurs as an adaptation to the impaired glucose tolerance. These mice clearly exhibited an impaired glucose tolerance that is due to defective insulin secretion because they do not exhibit an increase in insulin sensitivity. Together, these data indicate that the skeletal muscle selectively adapts to the global absence of AKAP150 to compensate for the decrease in insulin in the body. Notably, AKAP150 is also expressed in the liver but does not exhibit compensatory effects while AKAP150 is not expressed in the adipose tissue.AKAP150 can anchor numerous enzymes with different metabolic activities. For instance, it binds PKA and PP2B, two enzymes with opposing functions, to the cell surface membrane. Hinke et al (2012) further investigated the impact of disrupting specific binding partners of AKAP150. Unexpectedly, AKAP150Δ36 mice that lack residues 705–724 and therefore cannot bind PKA exclusively are effectively metabolically normal. It is thus surprising that the anchoring of PKA to AKAP150 is not necessary for proper insulin release although this interaction is important in other cellular systems (Lu et al, 2008, 2011). AKAP150ΔPIX mice lacking residues 655–661 and thus unable to tether to PP2B at a seven-residue PIxIxIT motif demonstrate the same metabolic phenotype as global AKAP150KO mice. This suggests that AKAP150 is critical for tethering PP2B, and that PP2B is the key molecule necessary for insulin secretion in β cells. PP2B is also a determinant of the metabolic phenotypes such as improved insulin sensitivity and glucose handling upon loss of anchorage of PP2B.Overall, Hinke et al (2012) used complementary in vivo approaches including animal physiology, and in vitro islet culture and live-cell imaging to demonstrate the importance of the kinase/phosphatase anchoring protein AKAP150 in regulating nutrient-stimulated insulin secretion and modulating glucose homeostasis in mice (Figure 1). However, it is likely that there are AKAP150-independent mechanisms regulating insulin secretion since islets from AKAP150KO mice continued to respond to glucose stimulation and secrete insulin in both static and dynamic conditions, albeit at lower levels compared to wild-type mice. Importantly, the authors also identified AKAP150 tethering to PP2B as a key molecular event that regulates insulin secretion and glucose homeostasis (Figure 1). Thus, targeting the AKAP150–PP2B interface and the PIxIxIT motif could be therapeutically useful for increasing insulin sensitivity in patients with diabetes and metabolic syndromes. This could involve designing molecules or chemical compounds to bind the motif and block interaction between AKAP150 and PP2B. In parallel, the safety of systemic blockade of this interaction needs to be ascertained. Alternatively, skeletal muscle-specific AKAP150ΔPIX mice could be generated to determine if the metabolic phenotype is similar to global AKAP150ΔPIX mice. Should this be the case, then localized pharmacological blockade of AKAP150–PP2B interaction could be considered.Open in a separate windowFigure 1AKAP150 tethered to PP2B at a seven-residue PIxIxIT motif mediates nutrient-stimulated insulin secretion and glucose homeostasis. Both global AKAP150KO and AKAP150ΔPIX (AKAP150-PP2B binding abolished) mice exhibit insulin secretory defects, enhanced insulin sensitivity in skeletal muscle and overall improved glucose tolerance. This infers the importance of AKAP150-PP2B tethering for glucose homeostasis. ‘Tick'' indicates an increase or improvement. ‘Cross'' indicates a defect or impairment. ‘Equal sign'' indicates no change or no effect. Questions emerging from this study are highlighted in red.Several issues worth pursuing include (1) determining the differential adaptive response of the skeletal muscle versus the liver to alterations in insulin sensitivity in global AKAP150KO mice, (2) further investigating the functional relevance of AKAP150 tethering to PKA (by generating β cell-specific AKAP150Δ36 mice) as there is probably a biological rationale for their interaction, (3) exploring whether AKAP150-related or other proteins are expressed and act in different adipose tissue depots, (4) determining whether AKAP150 acts in a similar manner in ‘human'' skeletal muscle and β cells, and (5) examining if polymorphisms in human genes that encode AKAP150 tethering proteins are linked to disorders of glucose metabolism.     

Oncogenic Pathway Combinations Predict Clinical Prognosis in Gastric Cancer

Many solid cancers are known to exhibit a high degree of heterogeneity in their deregulation of different oncogenic pathways. We sought to identify major oncogenic pathways in gastric cancer (GC) with significant relationships to patient survival. Using gene expression signatures, we devised an in silico strategy to map patterns of oncogenic pathway activation in 301 primary gastric cancers, the second highest cause of global cancer mortality. We identified three oncogenic pathways (proliferation/stem cell, NF-κB, and Wnt/β-catenin) deregulated in the majority (>70%) of gastric cancers. We functionally validated these pathway predictions in a panel of gastric cancer cell lines. Patient stratification by oncogenic pathway combinations showed reproducible and significant survival differences in multiple cohorts, suggesting that pathway interactions may play an important role in influencing disease behavior. Individual GCs can be successfully taxonomized by oncogenic pathway activity into biologically and clinically relevant subgroups. Predicting pathway activity by expression signatures thus permits the study of multiple cancer-related pathways interacting simultaneously in primary cancers, at a scale not currently achievable by other platforms.     

Attenuated Bordetella pertussis Protects against Highly Pathogenic Influenza A Viruses by Dampening the Cytokine Storm

The threat of a pandemic spread of highly virulent influenza A viruses currently represents a top global public health problem. Mass vaccination remains the most effective way to combat influenza virus. However, current vaccination strategies face the challenge to meet the demands in a pandemic situation. In a mouse model of severe influenza virus-induced pneumonitis, we observed that prior nasal administration of an attenuated strain of Bordetella pertussis (BPZE1) provided effective and sustained protection against lethal challenge with two different influenza A virus subtypes. In contrast to most cross-protective effects reported so far, the protective window offered upon nasal treatment with BPZE1 lasted up to at least 12 weeks, suggesting a unique mechanism(s) involved in the protection. No significant differences in viral loads were observed between BPZE1-treated and control mice, indicating that the cross-protective mechanism(s) does not directly target the viral particles and/or infected cells. This was further confirmed by the absence of cross-reactive antibodies and T cells in serum transfer and in vitro restimulation experiments, respectively. Instead, compared to infected control mice, BPZE1-treated animals displayed markedly reduced lung inflammation and tissue damage, decreased neutrophil infiltration, and strong suppression of the production of major proinflammatory mediators in their bronchoalveolar fluids (BALFs). Our findings thus indicate that protection against influenza virus-induced severe pneumonitis can be achieved through attenuation of exaggerated cytokine-mediated inflammation. Furthermore, nasal treatment with live attenuated B. pertussis offers a potential alternative to conventional approaches in the fight against one of the most frightening current global public health threats.Influenza virus pandemics are unpredictable but recurring events that can have severe consequences on societies worldwide. In the 20th century, three novel influenza virus strains emerged, causing the 1918, 1957, and 1968 pandemics, the most devastating being the 1918 Spanish flu that led to an estimated 50 million deaths (47). The recent spread of highly pathogenic avian influenza (HPAI) H5N1 virus across parts of Asia, Europe, and the Middle East, with an overall fatality rate of over 60% for humans, as well as the rapid pandemic spread of a novel influenza A virus of the H1N1 subtype, has caused worldwide concern about a potential remake of the 1918 disaster (8).Severe complications arising from pandemic influenza or HPAI H5N1 viruses are associated with rapid, massive inflammatory cell infiltration, resulting in acute respiratory distress, and reactive hemophagocytosis with multiple organ involvement. Both the 1918 Spanish influenza virus and HPAI H5N1 induce a cytokine storm characterized by an exaggerated production of inflammatory cytokines and chemokines in the serum and lungs caused by uncontrolled activation of the host''s innate immune system. This triggers massive pulmonary edema, primary and/or secondary pneumonia, and alveolar hemorrhage with acute bronchopneumonia (4, 12, 24, 27, 37, 40, 43, 44).The relationship between mortality, viral load, and immunopathology during influenza virus infection remains elusive and somewhat controversial. Some studies suggest that severe lung immunopathology is a direct consequence of a high viral load that the host is unable to resolve (12, 13), whereas others have reported that influenza virus-induced mortality is not a direct function of viral burden but a consequence of immune-mediated pathology (9, 11). Moreover, the picture is further complicated by the fact that different highly virulent influenza A viruses may induce distinct pathological signatures and lead to different courses of acute respiratory distress syndrome, refuting the hypothesis of a single, universal cytokine storm underlying all fatal influenza virus diseases (16).Currently, vaccination remains the cornerstone of influenza virus prevention. However, due to constant antigenic drift and shift of the two major viral surface proteins hemagglutinin (HA) and neuraminidase (NA) (7), influenza virus vaccines must be reformulated each year in order to match the circulating subtypes (41). The potential emergence of an influenza virus pandemic at any time, combined with limited vaccine supplies, has rendered global vaccination strategies difficult. Therefore, a universal influenza virus vaccine that can provide protection against different variants or strains and thus not require frequent updates is highly desirable.Here, we report that nasal administration of a recently developed live attenuated Bordetella pertussis vaccine strain, named BPZE1 (35), provides effective and sustained protection against lethal challenge with mouse-adapted H3N2 or H1N1 (A/PR/8/34) influenza A viruses. We demonstrate that the protective mechanism(s) does not target the viral particles or the infected host cells but controls the influenza virus-mediated inflammation by dampening the cytokine storm. As BPZE1 has recently entered phase I safety trials with humans (http://www.child-innovac.org), our observations support the potential application of this vaccine strain as a universal prophylactic treatment against highly pathogenic influenza A viruses.     

Upregulation of plasma C9 protein in gastric cancer patients

Gastric cancer is one of the leading causes of cancer‐related deaths worldwide. Current biomarkers used in the clinic do not have sufficient sensitivity for gastric cancer detection. To discover new and better biomarkers, protein profiling on plasma samples from 25 normal, 15 early‐stage and 21 late‐stage cancer was performed using an iTRAQ‐LC‐MS/MS approach. The level of C9 protein was found to be significantly higher in gastric cancer compared with normal subjects. Immunoblotting data revealed a congruent trend with iTRAQ results. The discriminatory power of C9 between normal and cancer states was not due to inter‐patient variations and was independent from gastritis and Helicobacter pylori status of the patients. C9 overexpression could also be detected in a panel of gastric cancer cell lines and their conditioned media compared with normal cells, implying that higher C9 levels in plasma of cancer patients could be attributed to the presence of gastric tumor. A subsequent blind test study on a total of 119 plasma samples showed that the sensitivity of C9 could be as high as 90% at a specificity of 74%. Hence, C9 is a potentially useful biomarker for gastric cancer detection.